Browsing Tag
Deramiocel
2 posts
Capricor Therapeutics (NASDAQ: CAPR) reports sustained efficacy and safety in 4-year DMD trial of Deramiocel
Capricor Therapeutics reports 4-year HOPE-2 data for Deramiocel in Duchenne, showing cardiac stability and slowed muscle decline. Read how it may shape future FDA decisions.
Capricor Therapeutics advances deramiocel toward FDA approval with priority review
Capricor Therapeutics has reached a significant milestone in its efforts to develop a novel treatment for Duchenne muscular…